Cargando…
A Case Report of Immune Checkpoint Inhibitor-Induced Aortitis Treated with Tocilizumab
Vasculitic immune checkpoint inhibitor-related adverse events (irAEs) are rare, with limited data to guide their management. Here, we present a case of a 67-year-old female with stage IV cutaneous melanoma who received first-line pembrolizumab. She had completed 21 cycles of pembrolizumab dosed at 2...
Autores principales: | Bloomer, Chance H., Annabathula, Rahul V., Aggarwal, Vanya, Upadhya, Bharathi, Lycan, Thomas W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581648/ https://www.ncbi.nlm.nih.gov/pubmed/36277471 http://dx.doi.org/10.1155/2022/7971169 |
Ejemplares similares
-
A Novel Workflow to Create a Checkpoint Inhibitor Pneumonitis Patient Registry
por: Faucheux, Andrew, et al.
Publicado: (2023) -
Early Initiation of Tocilizumab in Clinically Isolated Aortitis
por: Huang, Irvin J, et al.
Publicado: (2019) -
An Unusual Cause of Acute Abdominal Pain and Unexplained Dyspnea in a Young Man: A Sinus of Valsalva Aneurysm
por: Annabathula, Rahul V., et al.
Publicado: (2022) -
Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis
por: Doms, J., et al.
Publicado: (2020) -
Aortitis, with Special Reference to Syphilitic Aortitis
por: Campbell, S. B. Boyd
Publicado: (1922)